ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3

Receptor tyrosine kinases of the HER-family are involved in the development and progression of multiple epithelial tumors, and have consequently become widely used targets for new anti-cancer therapies. Trastuzumab, an antibody against HER2, has shown potent growth inhibitory effects on HER2 overexp...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Ebbing, Eva A., Medema, Jan Paul, Damhofer, Helene, Meijer, Sybren L., Krishnadath, Kausilia K., van Berge Henegouwen, Mark I., Bijlsma, Maarten F., van Laarhoven, Hanneke W. M.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891117/
https://ncbi.nlm.nih.gov/pubmed/26863569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7200
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items